Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats

Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats

Abstract Transporters can play a key role in the absorption, distribution, metabolism, and excretion of drugs. Understanding these contributions early in drug discovery allows for more accurate projection of the clinical pharmacokinetics. One method to assess the impact of transporters in vivo invol...

Full description

Bibliographic Details
Main Authors: Christopher Rowbottom, Alicia Pietrasiewicz, Taras Tuczewycz, Richard Grater, Daniel Qiu, Sudarshan Kapadnis, Patrick Trapa
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Pharmacology Research & Perspectives
Subjects:
blood‐brain barrier
BCRP
Breast cancer resistance protein
chemical and genetic knock out
dantrolene
efflux transporter
Online Access:https://doi.org/10.1002/prp2.740

Similar Items

Similar Items